Navigation Links
Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens
Date:8/1/2011

NEW YORK, Aug. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens

http://www.reportlinker.com/p0581172/Sustained-Release-Injectables-Evolving-Formulations-Improving-Dosing-Regimens .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug's release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.

Highlights

• Provides detailed analysis of sustained release injectable products, market segments, market dynamics and market demographics

• Analyzes therapeutic demand drivers and evaluates commercial sustained release injectables in eleven major therapeutic segments

• Charts sustained release product data and market share, and provides forecasts to 2015

• Profiles sustained release technology participants, their product development activities, business strategies, and corporate alliances and affiliations

Executive Summary

Injectable Drug Market Dynamics

The Trend toward Self-Administration

Shifting Demographics

Injectable Drug Formulation Technology

Innovation in Injectable Device Designs

Therapeutic Demand Drivers

Competitive Landscape

Risk Factors

Sustained Release Injectables - Branded Formulation Technologies

Biodegradable Polymers

PEG

PLG/PLA/PLGA

Polyether ester

Other Polymers

ChroniJect

CriticalMix

Depofoam

LinkeRx

Liposomes

Medisorb

Medusa

Optisomes

OxtoDEX

SABER/SAIB

Sucrose acetate isobutyrate

SynBiosys

Supercritical Fluid

Analysis of FDA Approved Sustained Release Injectables

cytarabine

goserelin acetate

Interferon

lanreotide acetate

leuprolide acetate

morphine

naltrexone

olanzapine

octreotide acetate

risperidone

paliperidone palmitate

somatostatin

triptorelin pamoate

Development-Stage SR Injectable Drug Candidate Assessment

Addiction

Antivirals

Hormones

Immune Modulators

Incretin Mimetics

Local Anesthetics

Opioid Antagonists

Psychotropics

Antineoplastics

SR Injectables – Therapeutic Sector Impact Analysis & Forecasts

Addiction

Autoimmune Diseases

Diabetes

Infectious Disease

Macular Degeneration

Metabolic Diseases

Neurology

Oncology

Pain Management

Reproductive Health

Sustained Release Injectables – Company Profiles

To order this report:

Drug and Medication Industry: Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens

Drug and Medication Business News

More  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
4. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
5. CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
6. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
7. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
10. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
11. Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... -- Dublin ... the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global market ... its applications in various applications. The report deals with ... main industries: pharmaceutical and biotechnology, food and beverage, and ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):